CPIX CUMBERLAND PHARMACEUTICALS INC

P/E --

Forward P/E 50

Price/Sales 2.871

Beta 0.037

Div Yield --

Market Cap --

Company Analysis

Latest News

October 25, 2026

Cumberland Pharmaceuticals Reports Positive Phase 2a Trial Results for Ifetroban

Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc clinical trial for its drug candidate, ifetroban. The study evaluated...